294 related articles for article (PubMed ID: 28626167)
1. A Human Glucagon-Like Peptide-1-albumin Recombinant Protein with Prolonged Hypoglycemic Effect Provides Efficient and Beneficial Control of Glucose Metabolism in Diabetic Mice.
Li C; Yang M; Hou G; Liu S; Huan Y; Yu D; Sun S; Liu Q; Yan S; Shen Z
Biol Pharm Bull; 2017 Sep; 40(9):1399-1408. PubMed ID: 28626167
[TBL] [Abstract][Full Text] [Related]
2. Effects of GW002, a novel recombinant human glucagon-like peptide-1 (GLP-1) analog fusion protein, on CHO recombinant cells and BKS-db mice.
Ji WW; Yu DA; Fan M; You M; Lu Y; Li EB; Xie N; Yan SS
Acta Diabetol; 2017 Jul; 54(7):685-693. PubMed ID: 28424924
[TBL] [Abstract][Full Text] [Related]
3. The albumin-exendin-4 recombinant protein E2HSA improves glycemic control and β-cell function in spontaneous diabetic KKAy mice.
Li C; Hou S; Liu S; Huan Y; Sun S; Liu Q; Shen Z
BMC Pharmacol Toxicol; 2017 Jun; 18(1):48. PubMed ID: 28629388
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterization and antidiabetic activity of a long-acting glucagon-like peptide-1 analogue conjugated to an antithrombin III-binding pentasaccharide.
Patterson S; de Kort M; Irwin N; Moffett RC; Dokter WH; Bos ES; Miltenburg AM; Flatt PR
Diabetes Obes Metab; 2015 Aug; 17(8):760-70. PubMed ID: 25929155
[TBL] [Abstract][Full Text] [Related]
5. Biological activity studies of the novel glucagon-like peptide-1 derivative HJ07.
Han J; Sun LD; Qian H; Huang WL
Chin J Nat Med; 2014 Aug; 12(8):613-8. PubMed ID: 25156287
[TBL] [Abstract][Full Text] [Related]
6. Effects of E2HSA, a Long-Acting Glucagon Like Peptide-1 Receptor Agonist, on Glycemic Control and Beta Cell Function in Spontaneous Diabetic db/db Mice.
Hou S; Li C; Huan Y; Liu S; Liu Q; Sun S; Jiang Q; Jia C; Shen Z
J Diabetes Res; 2015; 2015():817839. PubMed ID: 26351642
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
[TBL] [Abstract][Full Text] [Related]
8. An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.
Madsbad S; Kielgast U; Asmar M; Deacon CF; Torekov SS; Holst JJ
Diabetes Obes Metab; 2011 May; 13(5):394-407. PubMed ID: 21208359
[TBL] [Abstract][Full Text] [Related]
9. Effects of boschnaloside from Boschniakia rossica on dysglycemia and islet dysfunction in severely diabetic mice through modulating the action of glucagon-like peptide-1.
Lin LC; Lee LC; Huang C; Chen CT; Song JS; Shiao YJ; Liu HK
Phytomedicine; 2019 Sep; 62():152946. PubMed ID: 31102890
[TBL] [Abstract][Full Text] [Related]
10. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).
Young AA; Gedulin BR; Bhavsar S; Bodkin N; Jodka C; Hansen B; Denaro M
Diabetes; 1999 May; 48(5):1026-34. PubMed ID: 10331407
[TBL] [Abstract][Full Text] [Related]
11. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
Guo XH
Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
[TBL] [Abstract][Full Text] [Related]
12. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.
Maida A; Hansotia T; Longuet C; Seino Y; Drucker DJ
Gastroenterology; 2009 Dec; 137(6):2146-57. PubMed ID: 19766644
[TBL] [Abstract][Full Text] [Related]
13. Novel coumarin modified GLP-1 derivatives with enhanced plasma stability and prolonged in vivo glucose-lowering ability.
Han J; Sun L; Huang X; Li Z; Zhang C; Qian H; Huang W
Br J Pharmacol; 2014 Dec; 171(23):5252-64. PubMed ID: 25039358
[TBL] [Abstract][Full Text] [Related]
14. Exenatide upregulates gene expression of glucagon-like peptide-1 receptor and nerve growth factor in streptozotocin/nicotinamide-induced diabetic mice.
Gumuslu E; Cine N; Ertan M; Mutlu O; Komsuoglu Celikyurt I; Ulak G
Fundam Clin Pharmacol; 2018 Apr; 32(2):174-180. PubMed ID: 29091313
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment with EXf, a peptide analog of Exendin-4, improves β-cell function and survival in diabetic KKAy mice.
Hou GJ; Li CN; Liu SN; Huan Y; Liu Q; Sun SJ; Li LY; Hou SC; Shen ZF
Peptides; 2013 Feb; 40():123-32. PubMed ID: 23353893
[TBL] [Abstract][Full Text] [Related]
16. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations.
Greig NH; Holloway HW; De Ore KA; Jani D; Wang Y; Zhou J; Garant MJ; Egan JM
Diabetologia; 1999 Jan; 42(1):45-50. PubMed ID: 10027577
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological Effects of EGLP-1, a Novel Analog of Glucagon-Like Peptide-1, on Carbohydrate and Lipid Metabolism.
Gao H; Song Z; Zhao Q; Wu Y; Tang S; Alahdal M; Shen Y; Xing Y; Pan Y; Li J; Zhang Y; Jin L
Cell Physiol Biochem; 2018; 48(3):1112-1122. PubMed ID: 30041175
[TBL] [Abstract][Full Text] [Related]
18. GZR18, a novel long-acting GLP-1 analog, demonstrated positive in vitro and in vivo pharmacokinetic and pharmacodynamic characteristics in animal models.
Zhang M; Zhang Y; Peng X; He A; Wang Y; Deng Y; Cui C; Xue F; Wei B; Xing W; Qian Y; Mazuranic M; Chen W
Eur J Pharmacol; 2022 Aug; 928():175107. PubMed ID: 35718129
[TBL] [Abstract][Full Text] [Related]
19. Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R antibody fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites.
Li C; Yang M; Wang X; Zhang H; Yao C; Sun S; Liu Q; Pan H; Liu S; Huan Y; Li S; Cao J; Wang X; Guo Y; Guo N; Jing S; Zhang C; Shen Z
Biochem Pharmacol; 2018 Apr; 150():46-53. PubMed ID: 29355505
[TBL] [Abstract][Full Text] [Related]
20. Biological activity of AC3174, a peptide analog of exendin-4.
Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
